CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 52 enrolled
Drug / intervention
ZDV+3TC+LPV/rdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01818258
NCT01818258Phase 4Completed

IMPAACT 1092: Phase IV Evaluation Of The Steady State Pharmacokinetics Of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1-Infected Children

International Maternal Pediatric Adolescent AIDS Clinical Trials Group·interventional·Posted Mar 26, 2013·Updated Aug 12, 2021

In Brief

A Phase 4 clinical trial evaluating ZDV+3TC+LPV/r for HIV Positive and Malnourished. Completed, enrolled 52 participants across 5 sites in 4 countries.

Detailed Summary

Children living with HIV from sub-Saharan Africa often present with severe malnutrition. In severe malnutrition, metabolic and/or gut structural derangement may lead to inadequate antiretroviral (ARV) absorption and/or erratic drug levels. The greater surface area to weight ratio in severely malnourished children could also place them at higher risk of under dosing compared to children with mild to moderate malnutrition. However, limited data are available on the pharmacokinetics of ARVs in severely malnourished children. This study addressed this critical gap in knowledge by evaluating the PK of zidovudine (ZDV), lamivudine (3TC), and lopinavir/ritonavir (LPV/r) in severely malnourished children living with HIV, compared to children with normal nutrition to mild malnutrition living with HIV.

Study Details

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 26, 2013
Enrollment StartOct 26, 2015
Primary CompletionApr 11, 2017
Study CompletionSep 29, 2017
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.3 years ago

Interventions

ZDV+3TC+LPV/rdrug